Olynth Ha (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Olynth Ha, is a nasal decongestant presented as a topical nasal spray for intranasal use. It relieves nasal congestion associated with common colds, sinusitis, and allergic rhinitis in adults and children.

GNH USA supplies Olynth Ha as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olynth Ha contains Xylometazoline Hydrochloride, a sympathomimetic agent that acts on nasal mucosal blood vessels to reduce congestion. - Common cold: Provides rapid relief of nasal blockage and improves airflow. - Acute sinusitis: Decreases swelling of the nasal mucosa, facilitating drainage. - Allergic rhinitis: Alleviates nasal congestion caused by seasonal allergens. - Nasal surgery recovery: Helps maintain clear nasal passages post‑operatively.

Adverse reactions are generally mild and localized to the nasal cavity.

Common Side Effects: - Burning or stinging sensation in the nose. - Nasal dryness or irritation. - Sneezing shortly after application. - Mild headache. - Transient epistaxis (nosebleed).

Serious or Rare Side Effects: - Severe or persistent nosebleeds. - Allergic contact dermatitis affecting the nasal skin. - Rebound congestion after prolonged use (>5‑7 days). - Vision changes or ocular irritation if spray contacts the eyes.

When using Olynth Ha, consider the following safety measures: - Limit duration: Do not exceed 5‑7 consecutive days of use to avoid rebound congestion. - Pre‑existing conditions: Use cautiously in patients with hypertension, coronary artery disease, diabetes mellitus, or thyroid disorders. - Pediatric use: Follow prescriber guidance for children under 12 years of age. - Pregnancy & lactation: Use only if clearly needed and prescribed. - Drug interactions: Review concomitant nasal or systemic decongestants. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Xylometazoline may interact with other agents that affect vascular tone or adrenergic pathways.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): increased risk of hypertensive episodes. - Systemic sympathomimetic decongestants (oral pseudoephedrine): additive vasoconstriction.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: possible reduction in blood pressure‑lowering effect. - Beta‑blockers: may blunt the nasal decongestant response. - Topical ophthalmic vasoconstrictors: risk of ocular irritation if spray contacts eyes.